HLB Panagene Co., Ltd. (KOSDAQ:046210)

South Korea flag South Korea · Delayed Price · Currency is KRW
2,045.00
+106.00 (5.47%)
At close: Mar 6, 2026
-27.22%
Market Cap 86.76B
Revenue (ttm) 14.29B
Net Income (ttm) 1.68B
Shares Out 45.47M
EPS (ttm) 36.74
PE Ratio 51.94
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 281,673
Average Volume 498,526
Open 1,939.00
Previous Close 1,939.00
Day's Range 1,888.00 - 2,045.00
52-Week Range 1,535.00 - 2,950.00
Beta 0.23
RSI 51.18
Earnings Date Mar 13, 2026

About HLB Panagene

HLB Panagene Co., Ltd. manufactures and sells genetic diagnostic products in South Korea and internationally. It offers PANAMutyper, which detects small amount of mutation with high sensitivity and genotypes multiple mutations for oncology liquid biopsy; PNAClamp, a PNA-based PCR clamping that detects and amplifies only the mutated target DNA sequence for oncology tissue biopsy; PANA RealTyper, a PNA probe-based fluorescence melting curve analysis tool that detects mutation and distinguishes multiple SNPs adjacent for infectious diseases; PANA ... [Read more]

Industry In Vitro and In Vivo Diagnostic Substances
Founded 1976
Employees 82
Stock Exchange KOSDAQ
Ticker Symbol 046210
Full Company Profile

Financial Performance

In 2024, HLB Panagene's revenue was 13.20 billion, an increase of 7.71% compared to the previous year's 12.25 billion. Losses were -1.94 billion, -59.63% less than in 2023.

Financial Statements

News

There is no news available yet.